Mr. Carrie, thank you. You raised several points, but I'll address the last one first, because it brings it all together.
There is an ongoing commitment, a stated commitment, that the $88 million—the $28 million from the Gates Foundation and $60 million from the Government of Canada, amongst its agencies—is still on the table. There is currently an evaluation or assessment going on to determine where such funds should be spent. A multiple number of priorities are under consideration, including recognition of a need in Canada to support the transition from lab bench research to clinical research, and there might very well be a need to set a portion of that money aside to assist our researchers in accessing existing pilot-scale manufacturing facilities, whether in or outside of Canada.
Today, I shouldn't give you any assessment of what those various other priorities are, except that they span the range from research right into implementation of vaccines in needy areas. With the Gates Foundation and the other agencies in Canada, the original partners, or that family, if you like, of Canadian organizations, we are evaluating this almost as we speak. In fact, we have two more meetings on this today.